Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Antineoplastic Combined Chemotherapy Protocols
  • Esophageal Neoplasms
  • Stomach Neoplasms

abstract

  • We conclude that bortezomib is not effective for the treatment of advanced adenocarcinoma of the GEJ or stomach, whether used alone or in combination with irinotecan, in an unselected patient population.

publication date

  • January 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4047141

Digital Object Identifier (DOI)

  • 10.1007/s10637-014-0070-0

PubMed ID

  • 24526575

Additional Document Info

start page

  • 542

end page

  • 8

volume

  • 32

number

  • 3